FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 an...

Redirecting to full article...